Keyword
in
Collection
Date
to
Download Folder

0 items

Houston Voice, No. 1183, June 27, 2003
File 017
Citation
MLA
APA
Chicago/Turabian
Houston Voice, No. 1183, June 27, 2003 - File 017. 2003-06-27. University of Houston Libraries. University of Houston Digital Library. Web. December 16, 2017. http://digital.lib.uh.edu/collection/montrose/item/721/show/688.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

(2003-06-27). Houston Voice, No. 1183, June 27, 2003 - File 017. Montrose Voice. University of Houston Libraries. Retrieved from http://digital.lib.uh.edu/collection/montrose/item/721/show/688

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

Houston Voice, No. 1183, June 27, 2003 - File 017, 2003-06-27, Montrose Voice, University of Houston Libraries, accessed December 16, 2017, http://digital.lib.uh.edu/collection/montrose/item/721/show/688.

Disclaimer: This is a general citation for reference purposes. Please consult the most recent edition of your style manual for the proper formatting of the type of source you are citing. If the date given in the citation does not match the date on the digital item, use the more accurate date below the digital item.

URL
Embed Image
Compound Item Description
Title Houston Voice, No. 1183, June 27, 2003
Contributor
  • Weaver, Penny
  • Crain, Chris
Publisher Window Media
Date June 27, 2003
Language English
Subject
  • LGBTQ community
  • LGBTQ people
  • Gay liberation movement
Place
  • Houston, Texas
Genre
  • newspapers
Type
  • Text
Identifier OCLC: 31485329
Rights In Copyright: This item is protected by copyright. Copyright to this resource is held by the creator or current rights holder, and the resource is provided here for educational purposes. It may not be reproduced or distributed in any format without permission of the copyright owner. Users assume full responsibility for any infringement of copyright or related rights.
Note This item was digitized from materials loaned by the Gulf Coast Archive and Museum (GCAM).
Item Description
Title File 017
Transcript 16 JUNE 27, 2003 www.houston voice.com HOUSTON VOICE KALETRA® llopiDaivjr/ritonavir) capsules llcapinavir/ritonavir) onl solution -U.ERT: Kind oul jboul medicines thai should NOT be taken with KALETRA. Please also read the section "MEDICINES YOU SHOULD NOT TAKE WITH KALETRA.' Patient Information KALETRA® Ikuh-LEE-tra) Generic Name: lopinavir/ritonavir (l^aW-ijh-veer/ril-ON-uh-veer) Read (his leaflet carefully before you start taking KALETRA. Also, read it each dine you get your KALETRA prescription refilled, in case something has changed. This information does not take ihe place of lalking with your doctor when you start this medicine and il check ups. Ask your doctor if you have any questions about KALETRA. WlutiilOUnMamllKWdMjrtOTrIt? KALETRA is a combination of [wo medicines. They are lopinavir and ritonavir. KALETRA is a Type of medicine called an HIV (human immun odefciency virusj protease (PRO-tee-ascj inhibitor. KALETRA is always used in combination with other anti-HIV medicines to treat people with human immunodeficiency virus (HJV) infection. KALETRA is for adulls and for children age 6 months and older. HIV infection destroys CD., (T) cells, which arc important to (he immune system. After a large number of T cells are destroyed, acquired immune deficiency .yndrorne (AIDS) develops. KALETRA blocks HIV protease, a chemical which is needed for HIV to multiply. KALETRA reduces the amount of HIV in your blood and increases Ihe number of T cells. Reducing the amount of HIV in the blood -educes the chance of death or mfections thai happen when your immune system is weak 'opportunistic infections). Duel KALETRA eyre HIV or AIOS? KALETRA does not cure HIV infection or AIDS. The long-term effects of KALETRA are not known at this time. People taking KALETRA may still yet opportunistic in tec lions or other conditions that happen with HIY infection. Some of these conditions are pneumonia, herpes virus infections, and Mycobacterium avium complex I MAC) infections. Deis KALETRA reduce the risk ol pissing HIV lo others' KALETRA does not reduce the risk of passing HIV to others through sexual contact or blood contamination. Continue lo practice safe sex and do not use or share dirty needles. How shoele" I take KALETRA' • Yrw-toijJdtaayiindera doctor sc^ your neatmenl ur stop (reacment without lir-a talking with your doctor. • You must lake KALETRA every day exactly as your doctor prescribed il. The dose of KALETRA may be different for you than for other patients. Follow the directions from your doctor, exactly as written on the label. • Dosing in adults (including children 12 years of age and older): The usual dose for adults is 3 capsules (400/ lfJOin4lor5.0rnLc*iheor^soluw«tw« a day i rnornmg and night), m comNnamm with other am- • Dosing in children from 6 months to 12 yean of age: Children from 6 months to 12 years of age can also take KALETRA. The child's doctor will decide ihe nght dose based on the child's weight. • Take KALETRA with food to help it work better • Do not change your dose or stop taking KALETRA without first talking with your doctor. • When your KALETRA supply starts to run low, get more from your doctor or pharmacy. This is very important because the amount of virus in your blood may increase if ihe medicine is stopped for even a short time. The vims may develop resistance to KALETRA and become harder lo treat • Be stare lo set up a schedule and follow it carefully • Only take medicine rhat has been prescribed specifically for you Do not give KALETRA to others or take medicine prescribed for someone else. It is important that you do not miss any doses. If you miss a dose of KALETRA. lake it as soon as possible and then take your next Kbe-duled dose at its regular time. If it is almost time for your next dose, do not take the missed dose. Wait and take the next dose at the regular tune. Do not double the next dose WW UfHts il I take too leech KALETRA? If you suspect thai you look more than the prescribed dose of this medicine, contact yew local poison cootrol center or emergency room imrrwiaiely As wuh all prescription medicines. KALETRA should be kept out of ihe reach of young children. KALETRA liquid contains a Large amount of alcohol. If a toddler or young child accidentally drinks more than (he recommended dose of KALETRA. it could make him/her sick from loo much alcohol. Contact your local poison control center or emergency room irnirtediately if this happens. Who sbnwnottakt KALETRA' Together with your doctor, you need to decide whether KALETRA is right for you. • Do not lake KALETRA if you are taking certain medicines. These could cause scnous side effects that could cause death. Before you take KALETRA. you must tell your doctor about all me medicines you are taking or are planning to take. These include other prescription and nonprescription medicines and herbal supplements. For more mforrnaiion about medicines you should not lake with KALETRA, please read the section, tilled "MEDiaNES YOU SHOULD NOT TAKE WITH KALETRA." • Do rrf lake KAIETRA if;*™ lira anally ingredient-i inciiidinajj nkmav-'u w kir^rtavir. Cm I take KALETRA with other medications?' KALETRA may interact with other medicines, including those you take without a prescription. You must tell your doctor about all the medicines you are taking or planning to take before you lake KALETRA, MEDICINES YOU SHOULD NOT TAKE WITH KALETRA: • Do not take the following medicines with KALETRA because they can cause serious, problems or death if taken with KALETRA. - Dihydroergotamine. crgooovine. ergotamine and methylergonovine such as Cafergot*. Migranal* D.H.E. 45*, Ergotrate Maleate. Methergine, and others - Halcion* (triazolam) - Hismanal** tastemii-olcj - Orap* (pimoude) Propulsid* (cisapndej - Rythrool* (propafenone) - Seldane* (terfenadine) - Tambocot™ (flecainide) - Versed* (midazolam) • Do not take KALETRA wilh rifampin, aLso known as Rimactane*. Rifadin*. Rifatei*. or Rifamate* Rifampin may lower the amount of KALFTRA in your blood and make il less effective. ■ Do not take KALETRA with Si. John's wort (hypencum perforatumj. an herbal product sold as a dietary supplement, or products containing Si. John's wort Talk with your doctor if you are taking or planning to take Si John's wort Taking Si. John's wort may decrease KALETRA levels and lead to increased viral load and possible resistance to KALETRA or cross-resistance to other anti-HIV medicines. • Do not take KALETRA with the cholesterol-towering medicines Mevacor* (krvasiaiin) or Zocor* (simvastatin) because of possible serious reactions. There is also an increased risk of drug interactions between KALETRA and Lipitor* (atorvastatin); talk to your dotfi* before you take any of these cholesterol-reducing medicines with KALETRA. Medicines that require dosa-ac adiKtmnrts: Il is possible that your doctor may need lo increase or decrease the dose of other medicines when you are also taking KALETRA. Remember to tell your doctor all medicines you are taking or plan to lake. Before yon take Vtagra* fsiita-dl wtti l-LALF^ abort prrt-Mr-jm these two medicines can taut wheat taken Uvjether. You My get rtowrtd side effects of VIAGRA, s*d^ Iriw Morjd pr-r-am viHM crtfraer-s, ^ perw tMts lor*er than 4 bows, get maia^m^r.^ra^toatMptnmaiaM ill iiii; i f; p"~~ v~" rrlrrlnr ir ■■■■■*■■-■--•■■--•■ -i*mrHnnrti ;rn • If you are taking oral contraceptives ('the pill") to prevent pregnancy. you should use an additional or different type of contraception since KALETRA may reduce the effectiveness of oral contraceptives. • Efavirenz (Sustiva™) or nevirapine (Viramune*) may lower ihe amount of KALETRA in your blood. Your doctor may increase your dose of KALETRA if you are also taking efavirenz ot nevirapine. • If you are taking Mycobutin* (rifabutin), your doctor will lower the doseofMycofjutin. • A change in therapy should be o>nsackred if you are taking lULETRA with: Prt-enotaa-tjital Pherryioin I Dilantin* and others) Carbama/epine (Tegretol* and othersj These medicines may lower the amount of KALETRA in your Wood and make it less effective. • Other Special < KALETRA oral solution contains alcohol Talk with your doctor if you are taking or planning to take metronidazole or disulfiram Severe nausea and vomiting can occur. ■ If you are taking both didanosine | Videx*) and KALETRA: Didanosine (Videx*) should be taken one hour before or two hours after KALETRA What are the •folhle site effects of ULETRA? • This list of side effects is not complete If you have questions aboul side effecis, ask your (lector, nurse, or pharmacist. You should report any new or continuing syjnr^firns lo your doctor right away. Your doctor may be able lo help you manage these side effects. The most commonly reported side effects of moderate severity lhat are [bought lo be drug related are: abdominal pain, abnormal stools (bowel movements J. diarrhea, feeling weak/tired, headache, and nausea taking KALETRA may sometimes get a skin rash. inpatients laking KAIETRA may show possible liver prob- wiih liver disease such as Hepatitis B and Hepatitis C who :A may have worsening liver disease. Liver problems in-; 11(ding dcsih have occurred in patients taking KAIJTRA. In studies, it is nuclear if KALETRA caused these bver problems because some pailiertc had other illnesses or were laking other medicines • Some patterns taking KAliiTRA can develop serious problems with their pancreas (pancreatitisi, which may cause death You have a higher chance of having pancreatitis if you have had it before. Tell your doc* lor if you have nausea, vomiting, or abdominal pain. These may be signs of pancreatitis • Some patients have large increases in triglycerides and cholesterol. The long-lerm chance of gelling complications such as heart attacks or stroke due lo increases in triglycerides and cholesterol caused by protease inhibitors is not known at this time. • Diabetes and high blood sugar (hyperglycemia) occur in patients laking protease inhibitors such as KALETRA. Some patients had diabetes before starting protease inhibitors, others did not. Some patients need changes in their diabetes medicine. Others needed new diabetes medicine. • Changes in body fat have been seen in some patients taking antiretroviral therapy These changes may include increased amount of fat in the upper back and neck ("buffalo hump'), breast, and around ihe trunk. Loss of fat from (he legs, arms and face may also happen. The cause and long lerm health effects of these conditions are not known at this lime, • Some patients with hemophilia have increased bleeding with pmiea.se inhibitors. • There have been other side effects in pauenis laking KAIETRA, However, these side effecis may have been due lo other medicines thai pauenis were taking or io ihe illness itself. Some of these side effecis can be serious. What should I loll my doctor before laking KALETRA? • If you are pregnant or planning Ui become pregnant: The effects of KALETRA on pregnant women or their unborn babies are not known • If von are breast-feeding: Do not breast-feed if you are taking KALETRA You should not breast-feed if you have HIV If you arc a woman who has or will have a baby, talk with your doctor aboul the best way to feed your baby You should be aware that if your baby does not already have HIV, there is a chance that HIV can be Oansmiited through rrreast-feeding. • If you have liver problems: If you have liver problems or are infected wilh Hepatitis B or Hepatitis C. you should lell your doctor before taking KALETRA. • If you have diabetes: Some people laking protease inhibitors develop new or more scnous diabetes or high blood sugar. Tell your doctor if you have diabetes or an increase in thirst or frequent urination. • If you have hemophilia: Patients taking KALETRA may have increased bleeding. How io I store KALETRA? • Keep KALETRA and all other medicines oul of the reach of children. • Refrigerated KALETRA capsules and oral solution remain Ma-bes unit) the expiration date printed on ihe label. If stored at room temperature up to 77"F (25°Ct. KALETRA capsules and oral solution should be used within 2 months • Avoid exposure lo excessive heat. Do not keep medicine thai is out of date or lhat you no longer need. Be sure that if you throw any medicine away, il is oul of the reach of children. General a*rice aoeal ■reKription medicines: Talk to your doctor or other healthcare provider it yw have any questions aboul this medicine ur your condition. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. If you have any concerns aboul this medicine, ask your doctor Your doctor or pharmacist can give you information about this medicine Dial was written for health care professionals Do not use this medicine for a condition for which it was not prescribed. Do not share this mcdi cine with other people • The brands listed are trademarks of their respective owners and are not trademarks of Alihc* I^lwratories. Tne makers of ihese brands are not affiliated with arid do not endorse Abbott l-ahrtratori.es or its products. Ref 03 5239-R8 B3A^36-65IO-l MASTER Revised: January, 2003 1 ABBOTT UWOfliWOHES
File Name uhlib_31485329_n1183_016.jpg